How to Play HOLX Stock This Breast Cancer Awareness Month?
Hologic's breast health innovations, AI breakthroughs and leadership moves signal optimism ahead despite macro headwinds.
Illumina to Join Pharma Partners for CDx Development on KRAS Biomarker
ILMN partners with pharma leaders to advance KRAS-focused companion diagnostics through its TruSight Oncology platform.
Quest Diagnostics Joins Forces With Epic to Improve Laboratory Testing
DGX teams up with Epic on Project Nova to streamline lab testing, boost efficiency, and enhance patient and provider experiences.
PacBio Enters Carrier Screening Market With PureTarget Expansion
PACB expands its PureTarget portfolio, streamlining carrier screening with HiFi sequencing to meet rising global demand.
QuidelOrtho Expands Portfolio With the Launch of FDA-Approved Test
QDEL boosts its respiratory testing lineup with the FDA-cleared QUICKVUE Influenza + SARS Test for professional use.
DGX's Haystack Oncology Teams Up With Rutgers Cancer Institute
Quest Diagnostics' Haystack Oncology joins Rutgers Cancer Institute to study how its ctDNA MRD test can guide therapy for stage II/III lung cancer.
Tempus AI Enhances Cancer Research Tools With FDA-Cleared xR IVD
TEM secures FDA clearance for its xR IVD device, advancing RNA-based cancer research and precision medicine tools.
INCY Obtains FDA Approval for Label Expansion of Ruxolitinib Cream
Incyte secures FDA nod for Opzeluras pediatric use in atopic dermatitis, marking its third U.S. approval and boosting sales momentum.
QGEN Stock Gains From CE-IVDR Certification for QIAstat-Dx Portfolio
QIAGEN secures CE-IVDR certification for its full QIAstat-Dx portfolio, boosting its diagnostics arm and lifting shares.
Hologic's 2025 Outlook Improves on Strong Q3, Easing Tariff Headwinds
HOLX lifts its 2025 revenue and EPS outlook on Q3 strength, tariff relief, and growth across Breast Health and GYN Surgical.
QIAGEN Stock May Benefit From the US Clearance of QIAstat-Dx Rise
QGEN announces the launch of FDA-cleared QIAstat-Dx Rise, which may boost U.S. diagnostic access and testing capacity worldwide.
The Role of M&A in Hologic's Growth Story: Are More Deals in Sight?
HOLX fuels growth with targeted M&A across Diagnostics, Breast Health, and GYN Surgical, backed by a strong balance sheet.
Biobanking Market is expected to generate a revenue of USD 2.11 Billion by 2031, Globally, at 9.89% CAGR: Verified Market Research®
Lewes, Delaware, Aug. 25, 2025 ( GLOBE NEWSWIRE ) -- The Global Biobanking Market Size is projected to grow at a CAGR of 9.89% from 2024 to 2031, according to a new report published by Verified Market Research®.
INCY Stock Trading Close to Its 52-Week High: Buy, Sell or Hold?
Incyte hits a fresh 52-week high on strong Jakafi and Opzelura sales, pipeline wins and upbeat investor sentiment.
Veterinary Diagnostics Market is expected to generate a revenue of USD 4.52 Billion by 2031, Globally, at 6.59% CAGR: Verified Market Research®
Lewes, Delaware, Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- The Global Veterinary Diagnostics Market Size is projected to grow at a CAGR of 6.59% from 2024 to 2031, according to a new report published by Verified Market Research®.
Why Qiagen ( QGEN ) International Revenue Trends Deserve Your Attention
Examine the evolution of Qiagen's (QGEN) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
Baculovirus Expression System Market Poised for Significant Growth, Estimate to Hit USD 781.8 Million by 2032 | Coherent Market Insights
Burlingame, CA, Aug. 08, 2025 ( GLOBE NEWSWIRE ) -- The global Baculovirus Expression System Market is estimated to be valued at USD 436.0 Mn in 2025 and is expected to reach USD 781.8 Mn in 2032, exhibiting a compound annual growth rate ( CAGR ) of 8.7% from 2025 to 2032.
DoorDash To Rally Around 30%? Here Are 10 Top Analyst Forecasts For Thursday - AppLovin ( NASDAQ:APP ) , Crocs ( NASDAQ:CROX )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. UBS raised Qiagen N.V. QGEN price target from $48 to $50. UBS analyst John Sourbeer maintained a Neutral ...
Qiagen ( QGEN ) Matches Q2 Earnings Estimates
Qiagen (QGEN) delivered earnings and revenue surprises of 0.00% and +1.80%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
CERVOMED INC ( CRVO ) Surges 11.6%: Is This an Indication of Further Gains?
CERVOMED INC (CRVO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Why Qiagen ( QGEN ) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Is Hologic Stock a Risky Investment Ahead of Its Q3 Earnings Report?
HOLX heads into Q3 earnings with revenue and EPS estimates down, tariff pressures mounting, and stock lagging peers.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
QGEN or EXAS: Which Is the Better Value Stock Right Now?
QGEN vs. EXAS: Which Stock Is the Better Value Option?
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Is Hologic Stock's Low Valuation an Opportunity or a Value Trap?
HOLX trades below peers on P/S, but falling EPS, weak Breast Health sales and China risks cloud the outlook.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Incyte Gains 9.2% in Three Months: Buy, Hold or Sell the Stock?
INCY stock climbs 9.2% in three months as FDA approvals and a new diagnostic deal fuel pipeline momentum.
QGEN vs. EXAS: Which Stock Is the Better Value Option?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Qiagen ( QGEN Quick QuoteQGEN - ) and Exact Sciences ( EXAS Quick QuoteEXAS - ) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.
Qiagen ( QGEN ) Just Flashed Golden Cross Signal: Do You Buy?
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
Exosome Research Market is expected to generate a revenue of USD 646.52 Million by 2032, Globally, at 13.93% CAGR: Verified Market Research®
Lewes, Delaware, June 19, 2025 ( GLOBE NEWSWIRE ) -- The Global Exosome Research Market Size is projected to grow at a CAGR of 13.93% from 2026 to 2032, according to a new report published by Verified Market Research®.
QIAGEN's New QIAcuity dPCR IVD Pact With GENCURIX May Boost Its Stock
QGEN teams with GENCURIX to expand its digital PCR IVD offerings, aiming to strengthen its precision diagnostics arm.
Incyte Stock Rises on QIAGEN Deal to Advance Blood Cancer Diagnostics
INCY jumps 5.1% on a global QIAGEN deal to develop a companion diagnostic for its mutCALR-targeting cancer therapy.
QGEN Stock Rises in After Market Following Partnership With Incyte
QIAGEN teams up with Incyte to develop NGS-based companion diagnostics for blood cancers.
Why Incyte Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket - Battalion Oil ( AMEX:BATL ) , AIRO Group Holdings ( NASDAQ:AIRO )
Shares of Incyte Corporation INCY rose sharply in today's pre-market trading. QIAGEN and Incyte disclosed a precision medicine collaboration to develop companion diagnostics for patients with mutant CALR-expressing Myeloproliferative Neoplasms ( MPNs ) .
Should You Add QIAGEN Stock to Your Portfolio for Now?
QGEN rides on test menu growth, strategic partnerships, and strong solvency, despite macro and market headwinds.
Genomics Market to Hit US$66.8 Billion by 2029 with 9.4% CAGR | MarketsandMarkets™.
Delray Beach, FL, June 11, 2025 ( GLOBE NEWSWIRE ) -- The global genomics market, valued at US$42.4 billion in 2023, stood at US$42.6 billion in 2024 and is projected to advance at a resilient CAGR of 9.4% from 2024 to 2029, culminating in a forecasted valuation of US$66.8 billion by the end of ...
Can Hologic Lean on Its Strengths in a Tough Macroeconomic Climate?
HOLX grapples with global headwinds, but growth in Diagnostics and Breast Health service lifts confidence.
Qiagen ( QGEN ) Up 8.1% Since Last Earnings Report: Can It Continue?
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biomarker Market is expected to generate a revenue of USD 130.16 Billion by 2032, Globally, at 13.77% CAGR: Verified Market Research®
Lewes, Delaware, June 04, 2025 ( GLOBE NEWSWIRE ) -- The Global Biomarker Market Size is projected to grow at a CAGR of 13.77% from 2026 to 2032, according to a new report published by Verified Market Research®.
QGEN Stock to Gain From Expanding Oncology Portfolio via New Alliances
QIAGEN expands the oncology portfolio with new MRD testing alliances, setting the stage for personalized cancer care and stock growth.
QGEN Stock Might Gain Following New Partnership With ID Solutions
QGEN teams up with ID Solutions to boost QIAcuity's reach in oncology dPCR assays, aiming to strengthen its cancer research leadership.
Digital PCR and Real-Time PCR Market Size Worth USD 17.54 billion by 2031 at 9.1% CAGR | The Insight Partners
US & Canada, May 19, 2025 ( GLOBE NEWSWIRE ) -- According to a new comprehensive report from The Insight Partners, the global digital PCR and real-time PCR market is witnessing substantial growth with the surging incidence of genetic and infectious diseases and rising investments in gene ...
QIAGEN Stock Gains Following the Acquisition of Genoox
QGEN inks an agreement to acquire Genoox for $70 million in cash. The acquisition expands QIAGEN's QDI portfolio.
QGEN Q1 Earnings and Revenues Top, Operating Margin Expands, Stock Up
QGEN's quarterly performance benefits from a resilient portfolio in the first quarter of 2025.
Qiagen ( QGEN ) Q1 Earnings and Revenues Surpass Estimates
Qiagen (QGEN) delivered earnings and revenue surprises of 10% and 4.18%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Stay Ahead of the Game With Qiagen ( QGEN ) Q1 Earnings: Wall Street's Insights on Key Metrics
Get a deeper insight into the potential performance of Qiagen (QGEN) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Activist Fivespan has a stake in Qiagen. Here are 3 levers to boost the company's growth and improve value
Management at Qiagen has done the hard things right, but there is now an opportunity for the company to grow faster and in a more focused way.
QGEN or RGEN: Which Is the Better Value Stock Right Now?
QGEN vs. RGEN: Which Stock Is the Better Value Option?
Adaptive Biotechnologies ( ADPT ) Reports Q1 Loss, Tops Revenue Estimates
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 28.57% and 21.53%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
